Novo Nordisk (NOVO_B) Reports CagriSema Cut Weight 22.4% in 52 Weeks

Novo Nordisk reported that investigational CagriSema reduced body weight by 22.4% vs placebo at 52 weeks in an fMRI study and showed ectopic fat reductions in a diabetes sub-study, with additional bone marker findings in REIMAGINE 2.Material DetailsContext by AI AnalystThis is mid-to-late cycle cli…